Monte Rosa Therapeutics (NasdaqGS:GLUE) - Share price, News & Analysis

GLUE fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

GLUE Stock Overview

Risk Analysis

Earnings are forecast to decline by an average of 21.6% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Monte Rosa Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Monte Rosa Therapeutics
Historical stock prices
Current Share Price	US$7.63
52 Week High	US$45.56
52 Week Low	US$7.22
Beta	0
1 Month Change	-44.18%
3 Month Change	-47.31%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-63.98%

Recent News & Updates

Mar 04

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Sep 24

We're Not Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

	GLUE	US Biotechs	US Market
7D	-23.0%	4.8%	0.7%
1Y	n/a	-22.0%	-10.8%

Return vs Industry: Insufficient data to determine how GLUE performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how GLUE performed against the US Market.

Price Volatility

Is GLUE's price volatile compared to industry and market?
GLUE volatility
GLUE Average Weekly Movement	12.9%
Biotechs Industry Average Movement	12.3%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	2.9%

Stable Share Price: GLUE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: GLUE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2019	95	Markus Warmuth	https://www.monterosatx.com

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn’s disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies.

Monte Rosa Therapeutics Fundamentals Summary

How do Monte Rosa Therapeutics's earnings and revenue compare to its market cap?
GLUE fundamental statistics
Market Cap	US$354.37m
Earnings (TTM)	-US$85.61m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-4.1x

P/E Ratio

Is GLUE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
GLUE income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$85.61m
Earnings	-US$85.61m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-1.84
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did GLUE perform over the long term?

See historical performance and comparison

Valuation

Is Monte Rosa Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

1.09x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GLUE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GLUE's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: GLUE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: GLUE is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GLUE's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: GLUE is good value based on its PB Ratio (1.1x) compared to the US Biotechs industry average (1.4x).

Future Growth

How is Monte Rosa Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-21.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GLUE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GLUE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GLUE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GLUE is forecast to have no revenue next year.

High Growth Revenue: GLUE is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GLUE is forecast to be unprofitable in 3 years.

Past Performance

How has Monte Rosa Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-95.2%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: GLUE is currently unprofitable.

Growing Profit Margin: GLUE is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if GLUE's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare GLUE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GLUE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: GLUE has a negative Return on Equity (-26.27%), as it is currently unprofitable.

Financial Health

How is Monte Rosa Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: GLUE's short term assets ($320.4M) exceed its short term liabilities ($12.5M).

Long Term Liabilities: GLUE's short term assets ($320.4M) exceed its long term liabilities ($7.6M).

Debt to Equity History and Analysis

Debt Level: GLUE is debt free.

Reducing Debt: GLUE had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GLUE has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: GLUE has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 1.3% each year.

Dividend

What is Monte Rosa Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate GLUE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GLUE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GLUE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GLUE's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GLUE has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure

CEO

Markus Warmuth (50 yo)

2.33yrs

Tenure

US$4,954,317

Compensation

Dr. Markus Warmuth, M.D., serves on Board of Directors of Ventus Therapeutics U.S., Inc. since December 7, 2021. He serves as President, Chief Executive Officer and Director at Monte Rosa Therapeutics, Inc...

CEO Compensation Analysis

Compensation vs Market: Markus's total compensation ($USD4.95M) is above average for companies of similar size in the US market ($USD2.65M).

Compensation vs Earnings: Markus's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: GLUE's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Experienced Board: GLUE's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: GLUE only recently listed within the past 12 months.

Data	Last Updated (UTC time)
Company Analysis	2022/05/16 00:00
End of Day Share Price	2022/05/16 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31